Dec 1, 2019

Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration

Alzheimer's & Dementia : the Journal of the Alzheimer's Association
Nicholas T OlneyARTFL and LEFFTDS consortia

Abstract

The Advancing Research and Treatment in Frontotemporal Lobar Degeneration and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects longitudinal studies were designed to describe the natural history of familial-frontotemporal lobar degeneration due to autosomal dominant mutations. We examined cognitive performance, behavioral ratings, and brain volumes from the first time point in 320 MAPT, GRN, and C9orf72 family members, including 102 non-mutation carriers, 103 asymptomatic carriers, 43 mildly/questionably symptomatic carriers, and 72 carriers with dementia. Asymptomatic carriers showed similar scores on all clinical measures compared with noncarriers but reduced frontal and temporal volumes. Those with mild/questionable impairment showed decreased verbal recall, fluency, and Trail Making Test performance and impaired mood and self-monitoring. Dementia was associated with impairment in all measures. All MAPT carriers with dementia showed temporal atrophy, but otherwise, there was no single cognitive test or brain region that was abnormal in all subjects. Imaging changes appear to precede clinical changes in familial-frontotemporal lobar degeneration, but specific early clinical and imaging changes vary across i...Continue Reading

  • References22
  • Citations

References

  • References22
  • Citations

Citations

  • This paper may not have been cited yet.

Mentioned in this Paper

Research
Research Subject
Longitudinal Studies
Brain
Trail Making Test
C9orf72 gene
Frontotemporal Dementia
Self Monitoring
TNFSF10
Autosome

Related Feeds

Alzheimer's Disease: Early Markers

Alzheimer's disease is a chronic neurodegenerative disease. This feed focuses on early markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.

Alzheimer's Disease: RNA Sequencing

RNA sequencing is used to reveal the presence and quantity of RNA in a given sample. In this feed, RNA sequencing investigates the genetic and molecular mechanisms related to the pathophysiology of Alzheimer's disease (AD). Here are the latest discoveries pertaining to RNA sequencing and this disease.

Alzheimer's Disease: Genetics

Alzheimer's disease is a chronic neurodegenerative disease. Discover genetic and epigenetic aspects of Alzheimer’s disease, including genetic markers and genomic structural variations here.

Alzheimer's Disease: Neuroimaging

Alzheimer's disease (AD) is a chronic neurodegenerative disease. Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

ALS & FTD: TDP-43

ALS shares with a considerable proportion of FTD cases the same neuropathological substrate, namely, inclusions of abnormally phosphorylated protein tdp-43 (ptdp-43). Here are the latest discoveries pertaining to ptdp-43 and these diseases.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a chronic neurodegenerative disease. This feed focuses on the underlying role of Tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's.

Related Papers

Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
Knut Engedal
Fortschritte der Neurologie-Psychiatrie
J Diehl-SchmidH Förstl
Alzheimer's & Dementia : the Journal of the Alzheimer's Association
Adam M StaffaroniARTFL/LEFFTDS Consortium
Current Opinion in Neurology
Stephen SikkinkStuart M Pickering-Brown
© 2020 Meta ULC. All rights reserved